The increasing complexity of cancer chemotherapy makes it mandatory that pharmacists be familiar with these highly toxic agents. This column reviews various issues related to the preparation, dispensing, and administration of cancer chemotherapy, both commercially available and investigational.
Get full access to this article
View all access options for this article.
References
1.
BonadonnaG., BrusamolinoE., ValagussaP.Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med.1976; 294: 405–10.
2.
TanciniG., BonadonnaG., ValagussaP.Adjuvant CMF in breast cancer: Comparative 5-year results of 12 versus 6 cycles. J Clin Oncol.1983; 1: 2–10.
3.
FisherB., BrownA.M., DimitrovN.V.Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen nonresponsive tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol.1990; 8: 1483–96.
4.
BonadonnaG., RossiA., ValagussaP.The CMF program for operable breast cancer with positive axillary nodes. Cancer.1977; 39: 2904–15.
5.
FisherB., DignamJ., WolmarkN.Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst.1997; 89: 1673–82.
6.
BonadonnaG., ValagussaP., MoliterniA.Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. The results of 20 years of follow-up. N Engl J Med.1995; 332: 901–6.
7.
FisherB., DignamJ., MamounasE.P.Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. J Clin Oncol.1996; 14: 1982–92.
8.
GeorgeM.L., HaleP.C., GumpertJ.R.W.The use of neoadjuvant CMF to avoid mastectomy. Eur J Surg Oncol.1999; 25: 50–3.
9.
BonadonnaG., VeronesiU., BrambillaC.Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst.1990; 82: 1539–45.
10.
BonadonnaG., ZambettiM., ValagussaP.Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. JAMA.1995; 273: 542–47.
11.
HainsworthJ.D., JolivetJ., BirchR.Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma. Cancer.1997; 79: 740–8.
12.
TannockI.F., BoydN.F., DeBoerG.A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol.1988; 6: 1377–87.
13.
MoliterniA., BonadonnaG., ValagussaP.Cyclophosphamide, methotrexate, and fluorouracil with and without dox-orubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes. J Clin Oncol.1991; 9: 1124–30.
14.
EngelsmanE., KlijnJ.C.M., RubensR.D.“Classical” CMF versus a 3-weekly intravenous CMF schedule in post-menopausal patients with advanced breast cancer. Eur J Cancer.1991; 27: 966–70.
15.
MariniG., MurrayS., GoldhirschR.D.The effect of adjuvant prednisone combined with CMF on patterns of relapse and occurrence of second malignancies in patients with breast cancer. Ann Oncol.1996; 7: 245–50.
16.
TormeyD.C., GrayR., GilchristK.Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients. Cancer.1990; 65: 200–6.
17.
WoodW.C., WeissR.B., TormeyD.C.A randomized trial of CMF versus CMFVP as adjuvant chemotherapy in women with node-positive stage II breast cancer: A CALGB study. World J Surg.1985; 9: 714–8.
18.
JonesS.E., MoonT.E., BonadonnaG.Comparison of different trials of adjuvant chemotherapy in stage II breast cancer using a natural history data base. Am J Clin Oncol.1987; 10: 387–95.
19.
HortobagyiG.N.Treatment of breast cancer. N Engl J Med.1998; 339: 974–84.
20.
National Comprehensive Cancer Network.Update of the NCCN guidelines for treatment of breast cancer. Oncology.1999; 13(5A): 41–66.
21.
The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.Adjuvant systemic therapy for women with node-positive breast cancer. Can Med Assoc J.1998; 158(3 suppl): S52–S64.
22.
GoldhirschA., ColleoniM., CoatesA.S.Adding adjuvant CMF chemotherapy to either radiotherapy or tamoxifen: Are all CMFs alike?Ann Oncol.1998; 9: 489–93.
23.
GoldhirschA., CoatesA.S., ColleoniM.Adjuvant chemoendocrine therapy in postmenopausal breast cancer: cyclophosphamide, methotrexate, and fluorouracil dose and schedule may make a difference. J Clin Oncol.1998; 16: 1358–62.
24.
SobreroA.F., AscheleC., BertinoJrFluorouracil in colorectal cancer—a tale of two drugs: Implications for biochemical modulation. J Clin Oncol.1997; 15: 368–81.
25.
HeskethP.J., KrisM.G., GrunbergS.M.Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol.1997; 15: 103–9.
26.
American Society of Health-System Pharmacists.ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health-Syst Pharm.1999; 56: 729–64.
27.
National Comprehensive Cancer Network.NCCN antiemesis practice guidelines. Oncology.1997; 11: 57–89.
28.
BuserK.S., JossR.A., PiquetD.Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind, placebo-controlled study. Ann Oncol.1993; 4: 475–9.
29.
LevittM., WarrD., YelleL.Ondansetron compared with dexametha-sone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil. N Engl J Med.1993; 328: 1081–4.
30.
StillwellT.J., BensonR.C.Cyclophosphamide-induced hemorrhagic cystitis, a review of 100 patients. Cancer.1988; 61: 451–7.
American Society of Clinical Oncology.American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. J Clin Oncol.1994; 12: 2471–2508.
LymanG.H., KudererN., GreeneJ.The economics of febrile neutropenia: Implications for the use of colony-stimulating factors. Eur J Cancer.1998; 34: 1857–64.
